The study that reset the cannabis-cancer debate came from Gallagher and colleagues, published in the journal Lung Cancer in April 2026, and its headline number is blunt: adults with cannabis use disorder carried nearly four times the risk of developing lung cancer (RR = 3.87), a finding built on 20 years of electronic records from 67 U.S. health care organizations and matched cohorts of nearly 150,000 individuals per group.
Healio’s medical writers, Robert Glatter and Peter Papadakos, called the result a challenge to years of “unclear or conflicting” findings. The institutions and clinicians now driving the evidence are worth knowing by name, because each added a different piece.
Why earlier studies saw nothing
Pooled analyses and meta-analyses had long found no clear association between cannabis and lung cancer. A 2019 JAMA Network Open systematic review, cited in the Healio piece, diagnosed the problem: low cumulative exposure among participants, young cohorts, short follow-up and poor measurement of how much cannabis people actually smoked. The Gallagher team sidestepped that trap by selecting patients with a clinical diagnosis of cannabis use disorder, a proxy for heavy, sustained use, and so captured the high-exposure population earlier work kept missing. The elevated risk held across adenocarcinoma, squamous cell carcinoma and small cell carcinoma alike.
The USC clinicians behind the warning
At the Keck School of Medicine of USC, two names anchor the clinical evidence. Niels Kokot, an otolaryngologist, led a Keck Medicine study finding that heavy marijuana smokers showed higher rates of both small cell and non-small cell lung cancer, and reported elsewhere that daily users ran 3.5 to 5 times the risk of head and neck cancers, from the mouth and pharynx to the larynx and salivary glands. Thoracic surgeon Brooks Udelsman has become the voice of the caveats: “What we don’t know right now is the dose relationship”. Occasional users, he suspects, face minimal danger; the signal sits with “people who smoke a lot of marijuana — to the point that they develop a dependency on it or require hospital care or evaluation for it”.
The biology agrees
The mechanism story predates the statistics. Tobacco smoke carries more than 7000 chemicals, about 70 of them linked to cancer, and marijuana smoke shares many of them. Bronchial biopsies from habitual cannabis smokers show precancerous changes, squamous cell metaplasia, cellular atypia and DNA damage, similar to those in tobacco smokers, and joints deliver more tar per weight than cigarettes. The American Thoracic Society has acknowledged that cannabis smoke induces dysplasia, genomic toxicity and inflammatory changes. Udelsman’s summary is compact: “Anytime inflammation and changes to DNA occur, you’re at risk for developing cancer”.
Older signals, newly legible
A 40-year Swedish cohort had already linked heavy cannabis use beginning in young adulthood to a doubled lung cancer risk (HR = 2.12) even after adjusting for tobacco, and a French prospective study found 39% of young lung cancer patients were dual cannabis-tobacco smokers with more aggressive tumors. Put together, the case that heavy smoked cannabis is oncologically risky now rests on large-cohort epidemiology, histopathology and biology at once. In Healio’s words, “The era of reassuring patients that cannabis has no proven link to lung cancer is ending”. Uncertainty remains on dose, vaping and edibles; the direction of travel does not.
Sources
- Heavy marijuana smoking may increase cancer risk, researchers warn | ScienceDaily
- Lung cancer risks increase with cannabis use disorder
